|
1
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar
|
|
2
|
Harari D and Yarden Y: Molecular
mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene.
19:6102–6114. 2000. View Article : Google Scholar
|
|
3
|
Panis C, Pizzatti L, Corrêa S, Binato R,
Lemos GF, da Silva do Amaral Herrera AC, Seixas TF, Cecchini R and
Abdelhay E: The positive is inside the negative: HER2-negative
tumors can express the HER2 intracellular domain and present a
HER2-positive phenotype. Cancer Lett. 357:186–195. 2015. View Article : Google Scholar
|
|
4
|
Carney WP, Neumann R, Lipton A, Leitzel K,
Ali S and Price CP: Potential clinical utility of serum HER-2/neu
oncoprotein concentrations in patients with breast cancer. Clin
Chem. 49:1579–1598. 2003. View Article : Google Scholar
|
|
5
|
Liu PC, Liu X, Li Y, Covington M, Wynn R,
Huber R, Hillman M, Yang G, Ellis D, Marando C, et al:
Identification of ADAM10 as a major source of HER2 ectodomain
sheddase activity in HER2 overexpressing breast cancer cells.
Cancer Biol Ther. 5:657–664. 2006. View Article : Google Scholar
|
|
6
|
Rydén L, Landberg G, Stål O, Nordenskjöld
B, Fernö M and Bendahl PO: HER2 status in hormone receptor positive
premenopausal primary breast cancer adds prognostic, but not
tamoxifen treatment predictive, information. Breast Cancer Res
Treat. 109:351–357. 2008. View Article : Google Scholar
|
|
7
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical oncology/college of
American pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
9
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, et
al: Revision of the American joint committee on cancer staging
system for breast cancer. J Clin Oncol. 20:3628–3636. 2002.
View Article : Google Scholar
|
|
10
|
Ogston KN, Miller ID, Payne S, Hutcheon
AW, Sarkar TK, Smith I, Schofield A and Heys SD: A new histological
grading system to assess response of breast cancers to primary
chemotherapy: Prognostic significance and survival. Breast.
12:320–327. 2003. View Article : Google Scholar
|
|
11
|
Qi M, Li JF, Xie YT, Lu AP, Lin BY and
Ouyang T: Weekly paclitaxel improved pathologic response of primary
chemotherapy compared with standard 3 weeks schedule in primary
breast cancer. Breast Cancer Res Treat. 123:197–202. 2010.
View Article : Google Scholar
|
|
12
|
Ludovini V, Gori S, Colozza M, Pistola L,
Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C,
et al: Evaluation of serum HER2 extracellular domain in early
breast cancer patients: Correlation with clinicopathological
parameters and survival. Ann Oncol. 19:883–890. 2008. View Article : Google Scholar
|
|
13
|
Saghatchian M, Guepratte S, Hacene K,
Neumann R, Floiras JL and Pichon MF: Serum HER-2 extracellular
domain: Relationship with clinicobiological presentation and
prognostic value before and after primary treatment in 701 breast
cancer patients. Int J Biol Markers. 19:14–22. 2004. View Article : Google Scholar
|
|
14
|
Müller V, Witzel I, Lück HJ, Köhler G, von
Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, et
al: Prognostic and predictive impact of the HER-2/neu extracellular
domain (ECD) in the serum of patients treated with chemotherapy for
metastatic breast cancer. Breast Cancer Res Treat. 86:9–18. 2004.
View Article : Google Scholar
|
|
15
|
Fehm T, Jäger W, Krämer S, Sohn C,
Solomayer E, Wallwiener D and Gebauer G: Prognostic significance of
serum HER2 and CA 15-3 at the time of diagnosis of metastatic
breast cancer. Anticancer Res. 24:1987–1992. 2004.
|
|
16
|
Wang T, Zhou J, Zhang S, Bian L, Hu H, Xu
C, Hao X, Liu B, Ye Q, Liu Y and Jiang Z: Meaningful interpretation
of serum HER2 ECD levels requires clear patient clinical
background, and serves several functions in the efficient
management of breast cancer patients. Clin Chim Acta. 458:23–29.
2016. View Article : Google Scholar
|
|
17
|
Pohlmann PR, Mayer IA and Mernaugh R:
Resistance to trastuzumab in breast cancer. Clin Cancer Res.
15:7479–7491. 2009. View Article : Google Scholar :
|
|
18
|
Moretti D, Del Bello B, Allavena G and
Maellaro E: Calpains and cancer: Friends or enemies? Arch Biochem
Biophys. 564:26–36. 2014. View Article : Google Scholar
|
|
19
|
Storr SJ, Lee KW, Woolston CM, Safuan S,
Green AR, Macmillan RD, Benhasouna A, Parr T, Ellis IO and Martin
SG: Calpain system protein expression in basal-like and
triple-negative invasive breast cancer. Ann Oncol. 23:2289–2296.
2012. View Article : Google Scholar :
|
|
20
|
Chan D, Tsoi MY, Liu CD, Chan SH, Law SY,
Chan KW, Chan YP, Gopalan V, Lam AK and Tang JC: Oncogene GAEC1
regulates CAPN10 expression which predicts survival in esophageal
squamous cell carcinoma. World J Gastroenterol. 19:2772–2780. 2013.
View Article : Google Scholar :
|
|
21
|
Leloup L and Wells A: Calpains as
potential anti-cancer targets. Expert Opin Ther Targets.
15:309–323. 2011. View Article : Google Scholar :
|
|
22
|
Carney WP, Hamer PJ, Petit D, Retos C,
Greene R, Zabrecky JR, Mc Kenzie S, Hayes D, Kufe D, DeLellis R, et
al: Detection and quantitation of the human neu protein. J Tumor
Marker Oncol. 6:53–72. 1991.
|
